These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 4714097)

  • 1. Interactions of L-dopa and amantadine in patients with Parkinsonism.
    Cox B; Danta G; Schnieden H; Yuill GM
    J Neurol Neurosurg Psychiatry; 1973 Jun; 36(3):354-61. PubMed ID: 4714097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An analysis of six patients with Parkinson's disease who have been unresponsive to L-dopa therapy.
    Mones RJ
    J Neurol Neurosurg Psychiatry; 1973 Jun; 36(3):362-7. PubMed ID: 4714098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of amantadine, placebo, and levodopa in Parkinson's disease.
    Bauer RB; McHenry JT
    Neurology; 1974 Aug; 24(8):715-20. PubMed ID: 4858417
    [No Abstract]   [Full Text] [Related]  

  • 4. Amantadine hydrochloride in treatment of Parkinsonism.
    Nagaswami S; Nagaswami R
    Dis Nerv Syst; 1973; 34(5):253-8. PubMed ID: 4782280
    [No Abstract]   [Full Text] [Related]  

  • 5. Parkinson disease treated with a suspected dopamine receptor agonist.
    Chase TN; Woods AC; Glaubiger GA
    Arch Neurol; 1974 May; 30(5):383-6. PubMed ID: 4821783
    [No Abstract]   [Full Text] [Related]  

  • 6. Combined treatment of Parkinson's disease with amantadine and L-dopa.
    Scotti G
    Lancet; 1970 Jun; 1(7661):1394-5. PubMed ID: 4194144
    [No Abstract]   [Full Text] [Related]  

  • 7. Combined treatment of parkinsonism with L-dopa and amantadine.
    Godwin-Austen RB; Frears CC; Bergmann S; Parkes JD; Knill-Jones RP
    Lancet; 1970 Aug; 2(7669):383-5. PubMed ID: 4194690
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical evaluation of amantadine therapy for parkinsonism and the side effects--in cases of thalamic surgery and L-dopa therapy.
    Matsumoto K; Omoto T; Beck H
    Folia Psychiatr Neurol Jpn; 1974 Jan; 28(1):1-10. PubMed ID: 4406943
    [No Abstract]   [Full Text] [Related]  

  • 9. Amantadine versus L-2 dopa and amatadine plus L-dopa.
    Fieschi C; Nardini M; Casacchia M; Tedone ME; Reitano M; Robotti E
    Lancet; 1970 Jul; 2(7664):154-5. PubMed ID: 4194541
    [No Abstract]   [Full Text] [Related]  

  • 10. Plasma concentrations of L-dopa and 3-methoxydopa and improvement in clinical ratings and motor performance in patients with Parkinsonism treated with L-dopa alone or in combination with amantadine.
    Pilling JB; Baker J; Iversen LL; Iversen SD; Robbins T
    J Neurol Neurosurg Psychiatry; 1975 Feb; 38(2):129-35. PubMed ID: 1097598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of a dihydromorphanthridine derivative in Parkinson's patients treated with L-dopa. A preliminary report.
    Wycis HT
    Confin Neurol; 1972; 34(2):130-5. PubMed ID: 4666056
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson's disease.
    Parkes JD; Baxter RC; Marsden CD; Rees JE
    J Neurol Neurosurg Psychiatry; 1974 Apr; 37(4):422-6. PubMed ID: 4838913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The therapeutic possibilities of L-dopa and amantadine in Parkinsonian patients who have undergone bilateral thalamotomy.
    Giuffrè R; Gambacorta D
    Eur Neurol; 1971; 5(5):311-6. PubMed ID: 4943872
    [No Abstract]   [Full Text] [Related]  

  • 14. Combined L-dopa and amantadine in Parkinsonism.
    Pollock M; Jorgensen PB
    Aust N Z J Med; 1972 Aug; 2(3):252-5. PubMed ID: 4564049
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of Parkinson's disease with amantadine and L-Dopa.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1972; 7(4):228-40. PubMed ID: 4556618
    [No Abstract]   [Full Text] [Related]  

  • 16. [L-dopa treatment of parkinsonism].
    Szulc-Kuberska J; Niewodniczy A; Poźniak-Patewicz E; Wolczyk-Orzechowska M
    Neurol Neurochir Pol; 1973; 7(1):63-8. PubMed ID: 4511385
    [No Abstract]   [Full Text] [Related]  

  • 17. Amantadine in Parkinson's disease. A double-blind, placebo-controlled, crossover study with long-term follow-up.
    Butzer JF; Silver DE; Sahs AL
    Neurology; 1975 Jul; 25(7):603-6. PubMed ID: 807867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Responses of the urinary excretion of homovanillic acid and of 5-hydroxy-indol-acetic acid to treatment with L-dopa and amantadine.
    Molnár G; Fodor A
    Ther Hung; 1973; 21(1):35-40. PubMed ID: 4792890
    [No Abstract]   [Full Text] [Related]  

  • 19. Amantadine HCL (Symmetrel) and its relation to Levo-Dopa in the treatment of Parkinson's disease.
    Schwab RS; England AC
    Trans Am Neurol Assoc; 1969; 94():85-90. PubMed ID: 4907453
    [No Abstract]   [Full Text] [Related]  

  • 20. The effect of adding amantadine to optimum L-dopa dosage in Parkinson's syndrome.
    Fehling C
    Acta Neurol Scand; 1973; 49(2):245-51. PubMed ID: 4577929
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.